Avoiding Endocrine Disruptors Drops Diabetes Risk: Study

Based on epidemiological data, researchers estimate that reducing exposures to certain environmental chemicals could drop people’s chances of developing the disease.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, THIRTEEN OF CLUBSSome environmental chemicals, such as plastics additives and certain pesticides, act as endocrine disruptors and can perturb animals’ metabolisms in the lab. Epidemiological studies have also linked human exposures to these substances with an increased risk for developing diabetes. A study published today (October 27) in the Journal of Epidemiology & Community Health estimates that cutting exposures by 25 percent could reduce the prevalence of diabetes by 13 percent among the elderly in Sweden.

“Extrapolating to Europe, 152,481 cases of diabetes in Europe and €4.51 billion/year in associated costs could be prevented,” the authors, led by Leonardo Trasande at New York University School of Medicine, wrote in their report.

Trasande and his colleagues used data from a study of about 1,000 elderly Swedes whose blood was sampled to estimate their exposures to certain chemicals. Specifically, the researchers looked at four so-called “diabetogens”: two phthalates (plastics additives), a polychlorinated biphenyl (PCB), and PFNA, a surface-coating compound.

From the data they calculated a reduction in diabetes risk if exposure to each compound dropped by 25 percent. Although their estimates found reducing exposure to any one chemical didn’t make a difference, cutting back on all four together resulted in a 13 percent ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies